Skip to Main Content

In yet another rebuke to the pharmaceutical industry, nearly 22 percent of AbbVie (ABBV) shareholders voted in favor of a proposal that requires the drug maker to compile reports about the risks created by high prices and examine the extent to which pricing strategies propel executive compensation.

This marks the second time this week that a notable portion of shareholders in a big drug company have signaled that rising prices for medicines are a concern. On Tuesday, 22 percent of Bristol-Myers Squibb (BMY) stockholders also voted in favor of such a proposal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!